Relevance of α-defensins (HNP1-3) and defensin β-1 in diabetes

Table 1 Genotypes of DEFB1 G-20A, DEFB1 G-52A, and DEFB1 C-44G polymorphisms in patients with diabetes n (%)

DEFB1 G-20A	GG	GA	AA	χ2 test1
Patients with diabetes	82 (32)	131 (51)	44 (17)	0.568
n = 257
Type 1 diabetes	36 (31)	60 (51)	21 (18)	0.775
n = 117
Type 2 diabetes	46 (33)	71 (51)	23 (16)	0.573
n = 140
Controls	62 (31)	96 (48)	42 (21)
n = 200
DEFB1 G-52A	GG	GA	AA	χ2 test1
Patients with diabetes	114 (44)	104 (40)	39 (15)	0.572
n = 257
Type 1 diabetes	52 (44)	47 (40)	18 (17)	0.702
n = 117
Type 2 diabetes	62 (44)	57 (41)	21 (15)	0.658
n = 140
Controls	80 (40)	84 (42)	36 (18)
n = 200
DEFB1 C-44G	CC	CG	GG	χ2 test1
Patients with diabetes	156 (61) +	95 (37)	6 (2)2	0.002
n = 257
Type 1 diabetes	70 (60)	44 (37)	3 (2.5)	0.01
n = 117
Type 2 diabetes	86 (61)	51 (36)	3 (2)	0.003
n = 140
Controls	90 (45)	92 (46)	18 (9)
n = 200

¹χ² test vs controls;

²Fisher test vs controls, P = 0.001, OR = 9.136, 95%CI: 3.512-23.82; +: Fisher test vs controls, P = 0.0009, OR = 2.005, 95%CI: 1.218-2.746.